Valneva reports further positive pivotal phase 3 data in adolescents for its single-shot chikungunya vaccine

Results intended to support filing for potential label extension for use in adolescents saint-herblain (france), may 13, 2024 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today reported further positive pivotal phase 3 data in adolescents for its single-shot chikungunya virus (chikv) vaccine. following the initial analysis up to day 29 post-vaccination, the most recent analysis of study vla1553-321 evaluated the safety and immunogenicity six months (day 180) after vaccination with a single dose of the vaccine.
VALN Ratings Summary
VALN Quant Ranking